PharmaCyte Biotech to Attend Annual Meeting of the American Society of Clinical Oncology
26 May 2015 - 11:30PM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, today announced that its Chief
Executive Officer Kenneth L. Waggoner and Chief Operating Officer
Dr. Gerald W. Crabtree will attend the American Society of Clinical
Oncology's (ASCO) 51st annual meeting to be held May 29 through
June 2, 2015, at McCormick Place in Chicago. The theme of this
year's meeting is "Illumination & Innovation."
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte
Biotech, stated, "We believe that having PharmaCyte Biotech's
senior management team at this year's ASCO annual meeting will be
invaluable as we work to finalize the design of our three upcoming
clinical trials - the Phase 2b clinical trial comparing our
treatment for pancreatic cancer with the gold standard and the two
clinical trials involving the serious symptoms that accompany
advanced pancreatic cancer. The latter two will address the
unbearable and, often times, untreatable pain from pancreatic
cancer as well as the fluid (ascites) buildup in a patient's
abdomen that must be removed on a periodic basis for patients to
survive.
"Not only will Dr. Crabtree and I have the opportunity to
interact with those with whom PharmaCyte Biotech will be working
over the next two years, we will also be able to discuss our unique
treatment for advanced pancreatic cancer and the current state of
the design of our three clinical trials. All involve the
combination of the Cell-in-a-Box® live cell encapsulation
technology with low doses of the anticancer drug ifosfamide. We are
looking forward to having this opportunity to interact with our
colleagues in the pancreatic cancer field and to develop further
relationships with those who are attacking this most dreadful of
diseases."
ASCO is one of the world's largest organizations devoted to the
advancement of treatments for all types of cancer. Its annual
meetings are among the most well attended educational and
scientific meetings in the world. Over 32,000 individuals worldwide
have registered for this year's meeting, with 53% of these being
from outside the United States. More than 26,000 of the total
number of registrants are oncology professionals.
A record number (more than 5,900) of abstracts of presentations
have been submitted for consideration by ASCO. At this meeting,
reports of studies on all types of cancer will be presented. From
PharmaCyte Biotech's vantage point, presentations on pancreatic
cancer will be of paramount importance as well as presentations on
enrolling patients in clinical trials and pain management.
In addition to scientists and clinicians, representatives from
large and small pharmaceutical and biotech companies and Contract
Research Organizations, all with an interest in cancer, will be in
attendance. ASCO's annual meeting provides representatives from all
areas of the cancer spectrum the chance to interact and offers an
unparalleled opportunity for the free exchange of information among
meeting attendees.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech's treatment for pancreatic cancer involves low
doses of the well-known anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. These capsules are placed as close
to the cancerous tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug at the source of the
cancer. This "targeted chemotherapy" has proven remarkably
effective in past clinical trials.
PharmaCyte Biotech is also working towards improving the quality
of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors. In addition,
PharmaCyte Biotech is developing treatments for cancer based upon
chemical constituents of the Cannabis plant, known as cannabinoids.
In doing so, PharmaCyte Biotech is examining ways to exploit the
benefits of Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids, while minimizing or outright
eliminating the debilitating side effects usually associated with
cancer treatments. This provides PharmaCyte Biotech the rare
opportunity to develop "green" approaches to fighting deadly
diseases, such as cancer of the pancreas, brain and breast, which
affect hundreds of thousands of individuals worldwide every
year.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte Biotech or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They
include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in preclinical and clinical trials, flaws
or defects regarding its product candidates, changes in relevant
legislation or regulatory requirements, uncertainty of protection
of PharmaCyte Biotech's intellectual property and PharmaCyte
Biotech's continued ability to raise capital. PharmaCyte Biotech
does not assume any obligation to update any of these
forward-looking statements.
More information about PharmaCyte Biotech can be found at
www.PharmaCyte.com. It can also be obtained by contacting Investor
Relations.
CONTACT: Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com